Document is current
Any future updates will be listed below
-
Authors
Haggenmüller, Sarah
Wies, Christoph https://orcid.org/0000-0001-7136-298X
Abels, Julia
Winterstein, Jana T. https://orcid.org/0000-0003-3346-9537
Heinlein, Lukas https://orcid.org/0009-0009-5720-7700
Nogueira Garcia, Carina
Utikal, Jochen S. https://orcid.org/0000-0001-5316-0241
Wohlfeil, Sebastian A. https://orcid.org/0000-0003-4677-6149
Meier, Friedegund https://orcid.org/0000-0003-4340-9706
Hobelsberger, Sarah
Gellrich, Frank F. https://orcid.org/0000-0002-2164-4644
Sergon, Mildred
Hauschild, Axel
French, Lars E. https://orcid.org/0000-0002-4629-1486
Heinzerling, Lucie
Schlager, Justin G.
Ghoreschi, Kamran https://orcid.org/0000-0002-5526-7517
Schlaak, Max https://orcid.org/0000-0002-1663-8098
Hilke, Franz J.
Poch, Gabriela
Korsing, Sören
Sarfert, Cosimo
Berking, Carola https://orcid.org/0000-0003-0229-8931
Heppt, Markus V. https://orcid.org/0000-0003-4603-1825
Erdmann, Michael https://orcid.org/0000-0001-7136-6489
Haferkamp, Sebastian
Drexler, Konstantin
Schadendorf, Dirk https://orcid.org/0000-0003-3524-7858
Sondermann, Wiebke https://orcid.org/0000-0002-3684-3523
Goebeler, Matthias https://orcid.org/0000-0001-7095-9848
Schilling, Bastian https://orcid.org/0000-0001-8859-4103
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Llamas-Velasco, Mar
Requena, Luis C.
Ferrara, Gerardo https://orcid.org/0000-0003-0727-4015
Fernandez-Figueras, Maite https://orcid.org/0000-0002-2366-7110
Fraitag, Sylvie
Müller, Cornelia S. L.
Starz, Hans
Kutzner, Heinz
Barnhill, Raymond
Carr, Richard
Resnik, Kenneth S.
Braun, Stephan Alexander https://orcid.org/0000-0002-5600-0195
Holland-Letz, Tim
Brinker, Titus J. https://orcid.org/0000-0002-3620-5919
-
Funding
Funding for this research was provided by:
Bundesministerium für Gesundheit (Skin Classification Project 2)
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 10 January 2025
First Online: 17 January 2025
Competing interests
: Prof Utikal reported personal fees from Amgen, Bristol Myers Squibb, GSK, Immunocore, LEO Pharma, Merck Sharp & Dohme, Novartis, Pierre Fabre, Rheacell, Roche, and Sanofi outside the submitted work. Dr Wohlfeil received honoraria from Bristol Myers Squibb, Novartis, and Sun Pharma outside the submitted work. Prof Meier reported grants from Novartis and Roche and others (travel support or/and speaker’s fees or/and advisor’s honoraria) from BMS, MSD, and Pierre Fabre outside the submitted work. Dr Hobelsberger reported clinical trial support and advisor’s honoraria from Almirall, speaker’s honoraria from Almirall, UCB, and AbbVie, and travel support from UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma, and AbbVie outside the submitted work. Prof Heinzerling reported other (clinical studies) from BMS, MSD, Pierre Fabre, Replimune, and Sanofi; personal fees from Biomedx, BMS, MSD, Sun, Pierre Fabre, Novartis, and Sanofi; and grants from Therakos outside the submitted work. Prof Haferkamp reported speaker’s fees and advisor’s honoraria from BMS, MSD, Novartis, and Pierre Fabre outside the submitted work. Dr Schlaak reported personal fees from BMS, Novartis, Immunocore, Sun Pharma, MSD, Recordati, and Sanofi Aventis outside the submitted work. Prof Berking reported personal fees from BMS, MSD, InflaRx, Novartis, Sanofi, LEO Pharma, Almirall Hermal, Pierre Fabre, Immunocore, and Delcath outside the submitted work. Dr Erdmann received travel support and speaker’s honoraria from Immunocore, Novartis, Pierre Fabre, and Sanofi outside the submitted work. Dr Sondermann reported grants from Almirall, Novartis, and Medi GmbH; and personal fees from AbbVie, Almirall, BMS, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi Genzyme, and UCB outside the submitted work. Prof Goebeler reported grants for clinical studies from Argenx, Novartis, Janssen, and Galderma; personal fees from Almirall (consulting), Janssen (advisory board, speaker), GSK (advisory board, speaker), and Lilly (speaker) outside the submitted work. Dr Llamas-Velasco reported fees as an advisory board member, consultant, research support, participation in clinical trials, and honorary for speaking with the following pharmaceutical companies: Abbvie, Almirall, Amgen, Boehringer, BMS, Celgene, Janssen, Leo, Lilly, Kyowa kirin, Novartis and UCB, outside the submitted work. Dr. Kather declares consulting services for Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore, he holds shares in StratifAI GmbH, Germany, has received a research grant from GSK, and has received honoraria from AstraZeneca, Bayer, Eisai, Janssen, MSD, BMS, Roche, Pfizer, and Fresenius. Dr Gabriela Poch received travel support and speaker’s honoraria from MSD, BMS, Novartis, Sun Pharma, and Amgen outside the submitted work. Dr Brinker reported being the owner of Smart Health Heidelberg GmbH outside the submitted work. The remaining authors declare no competing interests.
